Preclinical Data from Tau-Targeting Program in the Central Nervous System Presented at the Alzheimer’s Association International Conference (AAIC) 2024

29 Jul, 2024 Preclinical Data from Tau-Targeting Program in the Central Nervous System Presented at the Alzheimer’s Association International Conference (AAIC) 2024

Preclinical data from a Tau-targeting program were presented at the Alzheimer’s Association International Conference (AAIC) 2024. An RNAi therapeutic development candidate leveraging Alnylam’s C16-siRNA CNS delivery platform was shown to achieve durable Tau-lowering for at least four months after a single intrathecal dose with an encouraging tolerability profile.

Kevin Sloan, et al, “A New Approach to Tau Lowering Using C16-siRNA Conjugates”